1. GSK takes RSV maternal vaccine candidate into phase 3 testing — FDA approves Alnylam's first-ever drug for rare kidney disease — FDA approves Roche's Xofluza to prevent flu spreading within families — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Foghorn hits Nasdaq in $120M debut as the biotech IPO boom shows no sign of slowing

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 12:12 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    17,934
    Likes Received:
    3
    via Since January, 72 biotech and biopharma companies have hit Wall Street, according to Nasdaq head of healthcare listings Jordan Saxe, together raising $13.2 billion.

    The latest is Flagship’s Foghorn Therapeutics, which priced its shares last night at $16 apiece, the midpoint of a $15 to $17 range.

    article source